Gouty Arthritis
Conditions
Interventions
Moderate-to-Severe Hyperuricemia Group (Serum Uric Acid >480 µmol/L)-Western Medicine Treatment Group:1.Basic Treatment (1) Diet: Avoid alcohol, adhere to a low-purine diet, and ensure sufficient dail
Mild Hyperuricemia Group (Serum Uric Acid =480 µmol/L)-Western Medicine Treatment Group:1.Basic Treatment (1) Diet: Avoid alcohol, adhere to a low-purine diet, and ensure sufficient daily water intake
Mild Hyperuricemia Group (Serum Uric Acid =480 µmol/L) -Traditional Chinese Medicine (TCM) Treatment Group:1.Basic Treatment (1) Diet: Avoid alcohol adhere to a low-purine diet and ensure sufficient d
Moderate-to-Severe Hyperuricemia Group (Serum Uric Acid >480 µmol/L) -Traditional Chinese Medicine (TCM) Treatment Group:1.Basic Treatment (1) Diet: Avoid alcohol, adhere to a low-purine diet, and ens
combined with Febuxostat Tablets (brand
Sponsors
Yueyang Hospital of Intergrated Traditional Chinese and Western Medicine Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1)Meet the Western diagnostic criteria for gouty arthritis. (2)Fulfill the Traditional Chinese Medicine (TCM) syndrome differentiation criteria for dampness-heat accumulation syndrome () in gouty arthritis. (3)Be in the intercritical period (remission phase) of gouty arthritis. (4)Aged 18–70 years regardless of gender. (5)History of gout >1 year with >4 acute flares annually. (6)No use of urate-lowering drugs (e.g. Febuxostat Allopurinol) within the past 1 month. (7)Voluntarily agree to participate in this clinical trial and comply with follow-up schedules. (8)Provide written informed consent.
Exclusion criteria
Exclusion criteria: (1)Acute polyarticular gout involving more than 4 joints. (2)Comorbid osteoarthritis rheumatoid arthritis or other arthritic diseases. (3)Severe primary diseases of the cardiovascular/cerebrovascular hepatic renal or hematopoietic systems; or psychiatric disorders. (4)Active gastrointestinal diseases or patients with gastrointestinal ulcers within the past 1 month. (5)Critically ill patients for whom the efficacy and safety of this clinical observation cannot be reliably evaluated. (6)Advanced arthritis with severe deformities stiffness or loss of working capacity. (7)Known hypersensitivity to the investigational drug(s) used in this study. (8)Patients planning pregnancy currently pregnant or lactating.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relapse Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Urinary Uric Acid;Symptom Severity Score;Mean Duration per Recurrence Episode;Urine pH;Serum Uric Acid ;Frequency of Acute Exacerbations;Treatment Efficacy Rate;Visual Analogue Scale (VAS) for Pain Intensity; | — |
Countries
China
Contacts
Public ContactMi Zhou
Yueyang Hospital of Intergrated Traditional Chinese and Western Medicine Shanghai University of Traditional Chinese Medicine
Outcome results
None listed